ClinicalTrials.gg
RecruitingNCT05357170Updated Jul 9, 2026

Microbiome Dysfunction in Surgical Intensive Care Unit Survivors

An observational study in Sepsis, Trauma Injury, sponsored by University of Florida. Recruiting at 1 site in United States. Open to participants aged 18 Years to 110 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by University of Florida · Observational

How we know

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
468
Ages
18 Years to 110 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Sepsis by University of Florida — 3 open to participants now, 6 under way, none of them phase 3. Sepsis · University of Florida.

Planned enrollment
2nd of 11
468 · median 110
Started
2022
with 2 others
Observational
11 of 15
3 open now
Registered
14th of 15
by date

Among the 15 studies in Sepsis by University of Florida, this one is the 2nd largest by planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2022, is one of 11 observational ones, and was the 14th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

3 of the 15 studies in Sepsis by University of Florida are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 110 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Sepsis by University of Florida, or all of them as a file.
02

Study summary

Oral and gastrointestinal microbiome dysfunction has been demonstrated to be a culprit of various systemic dysfunctions in peripheries such as cardiovascular, nervous, endocrine and musculoskeletal systems. The topic of microbiome dysfunction after surgical intensive care admission is understudied but may be responsible for persistent systemic inflammation clinically observed in surgical intensive care patients. Therefore, the objective of this project is to investigate the oral and gut microbiome after the acute phase of sepsis, severe trauma injury, cardiopulmonary bypass, and major vascular surgery to compare with 108 age-matched healthy population controls

Read the detailed description

The investigators hypothesize that alterations of the oral and gut microbiota will correlate with persistent systemic inflammation in surgical intensive care unit survivors compared to existing healthy population controls. This research group will collect oral and stool samples from 108 sepsis survivors, 108 trauma survivors, 108 cardiopulmonary bypass survivors, and major vascular surgery survivors (groups of ages 18-45, 46-64, and >65; male and female; n=18 per age + sex cohort) admitted to the surgical intensive care unit between day 7 and 28 of hospital admission, as well as 3 and 6 months after their intensive care unit hospitalization. The investigators will perform 16S rRNA DNA sequencing on the isolated bacterial DNA from these samples and bioinformatic analysis to determine microbiota alterations between time points and between surgical ICU survivor cohorts and a control cohort. In addition, the investigators will draw 20ml of blood to isolate plasma.

Trauma Subgroup for traumatic brain injury (TBI) pilot study: Our team will enroll 15 additional trauma injury patients with traumatic brain injury. This subgroup will have an added stool (if available) and blood sample collection after initial injury (+ 5 days). The additional sample will be compared to the sample collected at 14-21 days and follow up samples at 3 and 6 months. The results will be associated with Glasgow Outcome Scale Extended at 3 and 12 month time points and the recorded discharge Rancho Los Amigos scale score from the medical record. The specific aims will be: Aim 1 - define the impact of persistent systemic inflammation on the gastrointestinal microbiota in sepsis and trauma survivors and Aim 2 - identify microbial genes associated with persistent systemic inflammation in sepsis and trauma survivors compared to normal controls. Trauma Subgroup Aim: Pilot study to test the hypothesis that changes in the microbiome towards pathogenic microbe is associated with worsened outcomes in trauma injury patients with TBI (traumatic brain injury).

03

Conditions studied

  • Sepsis, Trauma Injury

Keywords

  • Sepsis; Trauma; Microbiome
04

Who can participate

Ages eligible
18 Years to 110 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Patients admitted to surgical intensive care units who screen positive for sepsis, have severe trauma injury, undergo cardiopulmonary bypass or major vascular surger and are being treated by our standard-of care ICU protocols are candidates for the study. Healthy adult volunteers will provide reference control samples.

Eligibility criteria

Sepsis Population

Inclusion Criteria

  1. Admission to the 46, 77, 87, 4 East, 4 West, or 24-5 ICUs where clinical care can be managed by the critical care organization guided by standard operating procedures.
  2. Age ≥18 years
  3. Meets Sepsis 3 criteria at time of sepsis diagnosis
  4. Has remained in ICU for 14 days (+/- 7 days) following sepsis diagnosis.
  5. Ability to obtain patient/LAR .
  6. Is receiving adequate nutritional intake: oral or enteral nutrition.

Exclusion Criteria

  1. Severe traumatic brain injury with unencumbered assessment of GCS equaling 3 on admission to intensive care unit
  2. shock (i.e., patients who are expected to die within 12 hours).
  3. Uncontrollable source of sepsis (e.g. irreversible disease state such as unresectable dead bowel).
  4. Patient or patient's family are not committed to aggressive management of the patient's condition.
  5. Known infection with \<200 cells/mm3.
  6. Organ transplant recipient on agents.
  7. Known pregnancy.
  8. Prisoners.
  9. Institutionalized patients j Inability to obtain informed consent.

k) Burn injury greater than 20% TBSA (total body surface area)

Trauma Population

Inclusion Criteria

1. All adults (age ≥18 to 54) require both:

a. Blunt and/or penetrating trauma patient with i. Hemorrhagic shock defined by:

1. Systolic BP (SBP) ≤ 90 mmHg or 2. Mean arterial pressure ≤ 65 mmHg or 3. Base deficit (BD) ≥5 meq or 4. Lactate ≥ 2 or 5. Active red blood cell or whole blood transfusion within 6 hours of arrival

b. Injury Severity Score (ISS) greater than or equal to 15

2. All adults (age 55 and older) require:

a. Either hemorrhagic shock defined by: i. Systolic BP (SBP) ≤ 90 mmHg or ii. Mean arterial pressure ≤ 65 mmHg or iii. Base deficit (BD) ≥5 meq or iv. Lactate ≥ 2 or v. Active red blood cell or whole blood transfusion within 6 hours of arrival

OR

b. Injury Severity Score (ISS) greater than or equal to 15. 3. Ability to obtain Informed Consent

Exclusion Criteria

  1. Patients not expected to survive greater than 48 hours.
  2. Prisoners.
  3. Pregnancy.
  4. Previous bone marrow transplantation.
  5. Patients with End Stage Renal Disease.
  6. Patients with any pre-existing hematological disease (e.g. hemochromatosis, myelodysplastic syndrome, hematologic cancers)
  7. Burn injury greater than 20% TBSA
  8. Severe traumatic brain injury with unencumbered assessment of GCS equaling 3 on admission to intensive care unit.

Trauma TBI subgroup (15 participants)

Inclusion criteria will be:

1. Any adult age 18 or older with any traumatic bleed (intracerebral hemorrhage, subarachnoid hemorrhage, intraparenchymal hemorrhage, subdural hematoma, cerebral epidural hematoma) and any GCS (Glasgow Coma Score).

Exclusion criteria is the same used for the trauma cohort.

Cardiac-Surgery operation:

Inclusion Criteria:

  1. Adult (>18 years age) patients undergoing open cardiac surgery
  2. Ability to obtain patient informed consent
  3. was placed on cardiopulmonary bypass at their initial operation at UF Health

Exclusion Criteria:

  1. Inability to obtain informed consent,
  2. Pregnancy
  3. Evidence of multi-organ failure on presentation
  4. Patients with any pre-existing hematological disease (e.g. hemochromatosis, myelodysplastic syndrome, hematologic cancers
  5. Prisoners
  6. Previous bone marrow transplantation
  7. Burn injury greater than 20% TBSA

Open abdominal vascular operation:

Inclusion Criteria:

  1. Adult (>18 years age) patients undergoing open abdominal vascular surgery
  2. Ability to obtain patient informed consent,

Exclusion Criteria:

  1. Inability to obtain informed consent,
  2. Pregnancy
  3. Evidence of multi-organ failure on presentation
  4. Patients with any pre-existing hematological disease (e.g. hemochromatosis, myelodysplastic syndrome, hematologic cancers
  5. Prisoners
  6. Previous bone marrow transplantation.
  7. Burn injury greater than 20% TBSA

Healthy Control

Inclusion criteria will be:

  1. All adults (age ≥18)
  2. Ability to obtain Informed Consent prior to blood collection.

Exclusion Criteria will be:

  1. Current, chronic use
  2. Pregnancy
  3. Current or recent (within 7 days) use of antibiotics.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
468 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Sepsis Survivors

    Oral swab, saliva, and feces collected between 7 to 28 days of hospital admission and at 3 and 6 months post hospitalization. Telephone call at 12 months. Blood will be collected at time of first feces collection

    Other: Human feces collection

  • Healthy Control Population

    One time collection of oral swab and saliva, feces, and blood upon enrollment used for comparison to identify microbial genes associated with persistent systemic inflammation in sepsis survivors.

    Other: Human feces collection

  • Trauma Survivor

    Oral swab, saliva, and feces collected between 7 to 28 days of hospital admission and at 3 and 6 months post hospitalization. Telephone call at 12 months. Blood will be collected at time of first feces collection

    Other: Human feces collection

  • Traumatic Brain Injury (TBI)

    Oral swab, saliva, and feces collected at admission (day 1(+5)) and between 7 to 28 days of hospital admission and at 3 and 6 months post hospitalization. Telephone call at 12 months. Blood will be collected at time of first and second feces collection.

    Other: Human feces collection

  • Cardiopulmonary Bypass

    Oral swab, saliva, and feces collected between 7 to 28 days of hospital admission and at 3 and 6 months post hospitalization. Telephone call at 12 months. Blood will be collected at time of first feces collection

    Other: Human feces collection

  • Major Vascular Surgery

    Oral swab, saliva, and feces collected between 7 to 28 days of hospital admission and at 3 and 6 months post hospitalization. Telephone call at 12 months. Blood will be collected at time of first feces collection

    Other: Human feces collection

Interventions

  • OtherHuman feces collection

    Oral swab and saliva, human feces collection and blood sampling

    Also known as: Blood sampling, Oral swab and saliva

06

What researchers measure

Primary outcomes

  1. Determine the impact of persistent systemic inflammation on oral and gastrointestinal microbiota in surgical ICU survivors & identify microbial genes associated with persistent systemic inflammation of surgical ICU survivors compared to normal controls.

    Identify oral and gut microbiome dysfunction through Microbial Taxonomic Analysis and Meta-transcriptomic Analysis

    Time frame: through study completion, an average of 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for May 2027, 59 months after the start.

Of 496 non-industry observational studies under Sepsis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 59 months is above that.

Counting every sponsor, half of 548 studies reached it within 27 months; a quarter within 12 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2022
First posted
May 2, 2022
StartActual
Jun 21, 2022
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2028
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05357170
Responsible party
Sponsor
First posted
May 2, 2022
Start date
Jun 21, 2022
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Jul 9, 2026

Study contacts

Ruth Davis, BSN
Contact
ruth.davis@surgery.ufl.edu
352-273-8759
Jennifer Lanz, MSN
Contact
jennifer.lanz@surgery.ufl.edu
352-273-5497
Philip Efron, MD
principal investigator · UF COM Department of Surgery

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion